v3.25.1
Segments (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Forth Disaggregated Research and Development Expenses

In addition to the significant expense categories included within net loss presented on the unaudited condensed consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

Direct research and development expenses:

 

 

 

 

 

CLYM116 1

$

9,120

 

 

$

—

 

Budoprutug

 

6,141

 

 

 

—

 

Legacy and cross-program expenses 2

 

299

 

 

 

74

 

Indirect research and development expenses:

 

 

 

 

 

Personnel expenses

 

1,757

 

 

 

943

 

Other research and development expenses 3

 

10

 

 

 

74

 

Total research and development expenses

$

17,327

 

 

$

1,091

 

 

1 Represents the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement.

2 Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155 and direct cross-program expenses.

3 Includes indirect expenses related to facility rent.